We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Alternative to Epilepsy Surgery Offered by MRI-Guided Laser Treatment

By HospiMedica International staff writers
Posted on 10 Jun 2014
For patients with mesial temporal lobe epilepsy (MTLE) that cannot be controlled by drugs, a minimally invasive laser procedure performed under magnetic resonance imaging (MRI) guidance provides a safe and effective alternative to surgery, according to new research.

The study’s findings were published in the June 2014 issue of Neurosurgery, the official journal of the Congress of Neurological Surgeons. More...
“Real-time magnetic resonance-guided stereotactic laser amygdalohippocampotomy [SLAH] is a technically novel, safe, and effective alternative to open surgery,” according to the new research by Dr. Robert E. Gross, from the Emory University School of Medicine (Atlanta, GA, USA) and colleagues.

The researchers report their experience with MRI-guided SLAH in 13 adult patients with epilepsy mapped to an area of the brain called the mesial temporal lobe. The patients, median age 24 years, had “intractable” seizures in spite of treatment with antiepileptic drugs.

In the SLAH procedure, a saline-cooled fiberoptic laser probe was precisely targeted to the brain region—the amygdalohippocampal complex. Using real-time MRI guidance, the neurosurgeon was able to target the area of the brain responsible for seizure activity and ablate by computer-controlled laser energy, without injuring the surrounding brain tissue.

The technical features of the procedure were effectively carried out in all patients. Using thermal imaging and MRI guidance, the surgeons were able to see the area of laser ablation as treatment proceeded. The average laser exposure time was just under 10 minutes. On average, 60% of the amygdalohippocampal complex was destroyed in the SLAH procedure; the average length of the ablated area was 2.5 cm. Median time spent in the hospital was only one day compared to a typical two to five-day stay after standard temporal lobe surgery, and SLAH patients did not have to be admitted to the intensive care unit.

Most significantly, the procedure was effective in lessening or eliminating seizures in patients with MTLE. At a median of 14 months after SLAH, 10 out of 13 patients achieved meaningful seizure reductions, while seven were free of disabling seizures. This included six out of nine patients whose epilepsy was caused by a defect called mesial temporal sclerosis. Although some complications occurred, none were directly caused by laser application. Two patients had an additional SLAH procedure to control seizures, and another patient underwent standard open surgery.

Open brain surgery is the standard treatment for patients with intractable MTLE. Surgery has a high success rate, but carries a significant risk of neurological and cognitive (intellectual) impairment. Minimally invasive approaches like the new MRI-guided laser ablation technique might produce similar seizure control with lower risks than surgery.

The new findings shows “technical feasibility and encouraging results” with the minimally invasive MRI-guided SLAH technique for patients with MTLE. Effectiveness in relieving or eliminating seizures approaches that of surgery—possibly in particular among patients whose seizures are caused by mesial temporal sclerosis. “These are promising results considering that this reflects our initial experience, and results may improve with greater experience with this novel technique,” noted Dr. Gross. “Such minimally invasive techniques may be more desirable to patients and result in increased use of epilepsy surgery among the large number of medically intractable epilepsy patients,” Dr. Gross and colleagues concluded. They stressed that a larger, longer-term study of SLAH is underway, including assessment of the effects on cognitive function as well as seizures.

Related Links:

Emory University School of Medicine



Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Electric Bed
DIXION Intensive Care Bed
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.